References
- 1. JEMAL A, SIEGEL R, WARD E, MURRAY T, XU J, SMIGAL C, et al. Cancer statics, 2006, CA Cancer J Clin, 56:106-130.
- 2. JABBOUR EJ, FADERL S, KANTARJIAN HM. Adult acute lymphoblastic leukemia. Mayo Clin Proc, 2005, 80:1517-1527.
- 3. MILLER DR, LEIKIN S, ALBO V, SATHER H, HAMMOND D. Prognostic importance of morphology (FAB classification) in childhood acute lymphoblastic leukemia (ALL). Br J Haematol, 1981, 48:199-206.
- 4. ROWE JM, BUCK G, BURNETT AK, CHOPRA R, WIERNIK PH, RICHARDS SM, LAZARUS HM, FRANKLIN IM, LITZOW MR, CIOBANU N, PRENTICE HG, DURRANT J, TALLMAN MS & GOLDSTONE AH. Induction therapy for adults with acute lymphoblastic leukaemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005; 106, 3760-3767.
- 5. JACOB M ROWE. Prognostic factors in adult acute lymphoblastic leukaemia. British Journal of Haematology, 2010, 150, 389-405.
- 6. MOORMAN AV, CHILTON L, WILKINSON J, et al. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood, 2010; 115:206.
- 7. MROZEK K, HARPER DP, APLAN PD. Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Hematol Oncol Clin North Am, 2009, 23(5):991-1010.
- 8. KENDERIAN S, LITZOW M. Clinical oncology in adolescents and young adult. 2013: 3 49-62.
- 9. FLEX E, PETRANGELI V, STELLA L, et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med, 2008, 205 (4):751-758.
- 10. ROBERTS K. Genetic profile in ALL - should all patients be screened? American Society of Hematology (ASH), 53rd Annual Meeting: Abstract 67. Presented December 12, 2011.
- 11. FIELDING AK, RICHARDS SM, CHOPRA R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL 12/ECOG 2993 study. Blood, 2007; 109: 944-950.
- 12. BASSAN R, HOELZER D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol, 2011; 29(5):532-43.